Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver C Lomas

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 1, 2020
Clinical Controversies in the Management of Smoldering Multiple MyelomaOliver C Lomas, Irene M Ghobrial
Current Opinion in Oncology|January 3, 2020
The microenvironment in myelomaOliver C Lomas, Sabrin Tahri, Irene M Ghobrial
Cancers|June 18, 2020
Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after AllOliver C Lomas, Tarek H Mouhieddine, Sabrin Tahri, et al.
British Journal of Haematology|August 2, 2021
The management of Castleman diseaseOliver C Lomas, Matthew Streetly, Guy Pratt, et al.
Leukemia|July 12, 2020
Genome instability in multiple myelomaCarl Jannes Neuse, Oliver C Lomas, Christoph Schliemann, et al.
Ejhaem|July 18, 2022
Validation of clinical-grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly-diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes ProjectOliver C Lomas, Sarah Gooding, Maite Cabes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug RegistrationKenneth C Anderson, Daniel Auclair, Stacey J Adam, et al.
The Lancet. Oncology|December 14, 2024
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational studyAnna Santarsieri, Emily Mitchell, My H Pham, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 1, 2020
Clinical Controversies in the Management of Smoldering Multiple MyelomaOliver C Lomas, Irene M Ghobrial
Current Opinion in Oncology|January 3, 2020
The microenvironment in myelomaOliver C Lomas, Sabrin Tahri, Irene M Ghobrial
Cancers|June 18, 2020
Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after AllOliver C Lomas, Tarek H Mouhieddine, Sabrin Tahri, et al.
British Journal of Haematology|August 2, 2021
The management of Castleman diseaseOliver C Lomas, Matthew Streetly, Guy Pratt, et al.
Leukemia|July 12, 2020
Genome instability in multiple myelomaCarl Jannes Neuse, Oliver C Lomas, Christoph Schliemann, et al.
Ejhaem|July 18, 2022
Validation of clinical-grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly-diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes ProjectOliver C Lomas, Sarah Gooding, Maite Cabes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug RegistrationKenneth C Anderson, Daniel Auclair, Stacey J Adam, et al.
The Lancet. Oncology|December 14, 2024
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational studyAnna Santarsieri, Emily Mitchell, My H Pham, et al.
Pageof 1